{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:53:41Z","timestamp":1791302021534,"version":"4.1.0"},"reference-count":22,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Jiangsu Provincial Medical Association-Aosikang Hospital Medical Science Foundation Project","award":["A202332"],"award-info":[{"award-number":["A202332"]}]},{"name":"Jiangsu Provincial Hospital Association-Hospital Management Innovation Research Project","award":["JSYGY-3-2024-667"],"award-info":[{"award-number":["JSYGY-3-2024-667"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2026,5,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Venetoclax (VEN), a selective BCL-2 inhibitor predominantly metabolized by CYP3A4, is a cornerstone therapeutic for myeloid neoplasms (MNs). Patients with myeloid malignancies are at elevated risk of invasive fungal infections (IFIs), and triazole antifungal drugs, such as posaconazole (PCZ) and voriconazole (VCZ), are commonly used for prophylaxis or treatment. These agents are potent CYP3A4 inhibitors and will exhibit significant potential for pharmacokinetic drug\u2013drug interactions with VEN. Although studies on their interaction are limited, such combinations are frequently used in clinical practice, making further research highly significant. This study aimed to investigate the changes in blood concentration and the safety of VEN when combined with triazole antifungal drugs (PCZ and VCZ). Patients with MN treated with VEN from April 2023 to April 2025 were enrolled and allocated to the VEN monotherapy group and the VEN plus triazole antifungal drug group. We collected baseline demographic characteristics and monitored adverse events. Steady-state plasma concentrations of VEN were quantified using the liquid chromatography\u2013mass spectrometry methodology. Statistical analyses, including comparative assessments of plasma concentrations and adverse event rates, were performed using IBM SPSS Statistics 26. A total of 54 patients were enrolled in the study. Following VEN dose reduction to 100 mg, plasma concentrations in the VEN + PCZ\/VCZ group remained significantly elevated compared to the VEN group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). However, the magnitude of this elevation did not differ significantly between the VEN + PCZ group and the VEN + VCZ group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.176). In addition, there was no linear correlation between VEN concentration and PCZ\/VCZ concentration. Safety analysis revealed no statistically significant differences between the two groups in the incidence of grade \u22653 hematological adverse events (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.214) or severe (grade \u22653) gastrointestinal adverse events (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.671). VEN combined with PCZ or VCZ resulted in significantly higher VEN exposure without a corresponding increase in severe hematological or gastrointestinal toxicity. This strategy effectively mitigates IFI risk without compromising the safety profile of VEN therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.01101-25","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:03:11Z","timestamp":1774980191000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of interactions between posaconazole\/voriconazole and venetoclax"],"prefix":"10.1128","volume":"70","author":[{"given":"Chunqing","family":"Liu","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01sfm2718","id-type":"ROR","asserted-by":"publisher"}],"name":"School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University","place":["Nanjing, China"]},{"id":[{"id":"https:\/\/ror.org\/04gz17b59","id-type":"ROR","asserted-by":"publisher"}],"name":"Faculty of Pharmacy, Northern Jiangsu People's Hospital","place":["Yangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Xie","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04gz17b59","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Hematology, Northern Jiangsu People's Hospital","place":["Yangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Sun","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04gz17b59","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Hematology, Northern Jiangsu People's Hospital","place":["Yangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengzhou","family":"Hang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04gz17b59","id-type":"ROR","asserted-by":"publisher"}],"name":"Faculty of Pharmacy, Northern Jiangsu People's Hospital","place":["Yangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxiu","family":"Lyu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04gz17b59","id-type":"ROR","asserted-by":"publisher"}],"name":"Faculty of Pharmacy, Northern Jiangsu People's Hospital","place":["Yangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Shi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04gz17b59","id-type":"ROR","asserted-by":"publisher"}],"name":"Faculty of Pharmacy, Northern Jiangsu People's Hospital","place":["Yangzhou, China"]},{"name":"College of Pharmacy, Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gao","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04gz17b59","id-type":"ROR","asserted-by":"publisher"}],"name":"Faculty of Pharmacy, Northern Jiangsu People's Hospital","place":["Yangzhou, China"]},{"name":"College of Pharmacy, Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8060-3131","authenticated-orcid":false,"given":"Wenjun","family":"Xu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04gz17b59","id-type":"ROR","asserted-by":"publisher"}],"name":"Faculty of Pharmacy, Northern Jiangsu People's Hospital","place":["Yangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1877-2467","authenticated-orcid":true,"given":"Hua","family":"Zhu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04gz17b59","id-type":"ROR","asserted-by":"publisher"}],"name":"Faculty of Pharmacy, Northern Jiangsu People's Hospital","place":["Yangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26589"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/imj.15588"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02586-7"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad143"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2024.11.012"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01306-y"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115759"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13807"},{"key":"e_1_3_4_10_2","unstructured":"National Cancer Institute. 2025. Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0). Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30010-X"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0453-9"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.31547\/bct-2020-025"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025464"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.2174\/0115748928330206241104161111"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1539233"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13175"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad134"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-022-03289-9"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-020-04179-w"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.2017.0430"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33508B1"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2140"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01101-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01101-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T13:02:40Z","timestamp":1778072560000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01101-25"}},"subtitle":[],"editor":[{"given":"Andreas H.","family":"Groll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,6]]}},"alternative-id":["10.1128\/aac.01101-25"],"URL":"https:\/\/doi.org\/10.1128\/aac.01101-25","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"2025-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01101-25"}}